Search

Displaying results 1181 - 1190 of 2160 in total
  1. Drug

    Supinoxin

    go.drugbank.com/drugs/DB19010
    Investigational

    Supinoxin is under investigation in clinical trial NCT02003092 (RX-5902 Treatment of Subjects With Triple Negative Breast Cancer).

    Synonyms: P-p68 inhibitor rx-5902
  2. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  3. Drug

    Decitabine

    go.drugbank.com/drugs/DB01262
    ApprovedInvestigational

    Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplasms with variable underlying etiology and presentation, including neutropenia and thrombocytopenia. Further mutations leading to increased proliferation of ...

  4. Drug

    Macadamia seed oil glycereth-8 esters

    go.drugbank.com/drugs/DB14318
    Investigational

    Macadamia seed oil glycereth-8 esters is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Damoctocog alfa pegol

    go.drugbank.com/drugs/DB14700
    ApprovedInvestigational

    In recent years, various extended half-life factor VIII and factor IX preparations have been studied and gained approval.

  6. Drug

    Luspatercept

    go.drugbank.com/drugs/DB12281
    ApprovedInvestigational

    Luspatercept is a recombinant fusion protein comprised of a modified extracellular domain of activin receptor type IIB fused to the FC domain of human IgG1. It was first approved for use in the United States in November 2019 under the br...

  7. Drug

    Lemborexant

    go.drugbank.com/drugs/DB11951
    ApprovedInvestigational

    [A189006] This novel mechanism of action offers potential advantages over classic hypnotic agents, including a more favorable adverse effect profile and potentially greater efficacy, and may signal the

  8. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808] ROS1 gene fusions drive a small subset of non-small cell lung cancers, and while several ROS1 inhibitors are available, treatment is limited over time by two recurring problems: the emergence

  9. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease. Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glu...

  10. Drug

    Fruquintinib

    go.drugbank.com/drugs/DB11679
    ApprovedInvestigational

    Fruquintinib is a novel small-molecule anti-VEGFR that targets VEGFR-1,-2, and -3 to inhibit angiogenesis. Tumor angiogenesis is one of the most critical biological processes for increasing oxygen and nutrient supply to cancer cells, and...